Drug retention of TNFi vs. secukinumab in AxSpA pts Abs#911 ⭐️46% discontinued either treatment ⭐️TNFi with slightly better drug retention ⭐️Age, BASDAI, BMI did not favor any group ⭐️inefficacy - main reason #ACR21 @RheumNow https://t.co/ynoomYrTvX

Dr. Alexis Ogdie on opioid use in PsA and axSpA, highlighting need for better interventions. 🔹21% of PsA pts (n=828) and 27% of axSpA (n=334) reported prescription opiate use. 🔹⬆️BASDI & HAQ-DI =>⬆️opiate use & costs https://t.co/Id658ocDVf #ACR21 Abst1777 @RheumNow

• Association of Opioid Use and Opioid-Related Costs with Patient-Reported Outcom…

AxSpA/ PsA pts who completed ePRO Q between 2018-2021 showed 🔽 trend of PRO mostly in pts on biologic Rx If ASDAS < 1.3 /PSAID-12 < 2➡️ pts were seen less frequently ⭐️🔽 clinic workload and better disease activity stratification Abst # 1788 #ACR21 @RheumNow #ACRBest https://t.co/ilSrOjHQAk

Dose Tapering of TNFi in AxSpA: Dr. Antoni Chan ( @synovialjoints) discusses abstract #0364 presented at the #ACR21 annual meeting. https://t.co/pDnKFfeQdP https://t.co/7CZg2lkSFI

• https://bit.ly/3qjAs4E

Hospitalisation for heart failure ⬆️ in inflammatory diseases. RA>PsA>AS>PsO . HRs 1.1-1.6 compared to general population. Abstr#1925 #ACR21 @RheumNow https://t.co/kKlGQM5Tcg

Why is there more CHF in #RheumatoidArthritis ? Also dose response between highest inflammation RA the PsA then axSpA then PsO. ?Cytokine profile varying with disease and maybe CRP. Who knows. Abst#1925 #ACR21 @RheumNow https://t.co/JIH3qwkLpx

• Richard Conway on Twitter: &quot;Hospitalisation for heart failure ⬆️ in inflam…